Rifampicin(continued)
▶Rifampicinis predicted to decrease the efficacy of
levonorgestrel. For FSRH guidance, seeContraceptives,
interactionsp. 497.rTheoretical
▶Rifampicinis predicted to decrease the exposure tolinagliptin.
oStudy
▶Rifampicinslightly decreases the exposure tolinezolid.
oStudy
▶Rifampicinis predicted to decrease the exposure tolomitapide.
Monitor and adjust dose.oTheoretical
▶Rifampicinincreases the clearance oflorazepam.o
Study
▶Rifampicinis predicted to decrease the exposure tolurasidone.
Avoid.oStudy
▶Rifampicinis predicted to decrease the exposure to
macitentan. Avoid.rStudy
▶Rifampicindecreases the concentration ofmacrolides
(clarithromycin).rStudy
▶Rifampicinis predicted to decrease the exposure tomaraviroc.
Adjust dose.rStudy
▶Rifampicinis predicted to decrease the exposure tomelatonin.
oTheoretical
▶Rifampicinis predicted to decrease the exposure tomidazolam.
Monitor and adjust dose.oStudy
▶Rifampicinis predicted to decrease the exposure to
midostaurin. Avoid.rStudy
▶Rifampicinis predicted to decrease the exposure to
mirtazapine. Adjust dose.oStudy
▶Rifampicinis predicted to decrease the exposure tomodafinil.
oTheoretical
▶Rifampicindecreases the effects ofmonoclonal antibodies
(brentuximab vedotin).rStudy
▶Rifampicinis predicted to decrease the exposure to
montelukast.nStudy
▶Rifampicindecreases the concentration ofmycophenolate.
Monitor and adjust dose.rStudy
▶Rifampicinis predicted to markedly decrease the exposure to
naloxegol. Avoid.oStudy
▶Rifampicinis predicted to slightly decrease the exposure to
nateglinide.nStudy
▶Rifampicinis predicted to decrease the exposure tonetupitant.
Avoid.rStudy
▶Rifampicindecreases the concentration ofnevirapine. Avoid.
rStudy
▶Rifampicinis predicted to moderately decrease the exposure
tonilotinib. Avoid.rStudy
▶Rifampicinis predicted to decrease the exposure tonintedanib.
oStudy
▶Rifampicinis predicted to decrease the exposure tonitisinone.
Adjust dose.oTheoretical
▶Rifampicinincreases the clearance ofnitrazepam.o
Study
▶Rifampicinis predicted to decrease the efficacy of
norethisterone. For FSRH guidance, seeContraceptives,
interactionsp. 497.rAnecdotal
▶Rifampicinmoderately decreases the exposure toNSAIDs
(celecoxib, diclofenac, etoricoxib).oStudy
▶Rifampicinis predicted to decrease the exposure toolanzapine.
Monitor and adjust dose.oStudy
▶Rifampicinis predicted to decrease the exposure toolaparib.
Avoid.oTheoretical
▶Rifampicinis predicted to decrease the exposure toombitasvir.
Avoid.rTheoretical
▶Rifampicinis predicted to decrease the exposure to
ondansetron.oStudy
▶Rifampicinis predicted to decrease the exposure toopioids
(alfentanil, fentanyl).oStudy
▶Rifampicinis predicted to decrease the exposure toopioids
(buprenorphine). Monitor and adjust dose.oTheoretical
▶Rifampicindecreases the exposure toopioids(codeine,
morphine).oStudy
▶Rifampicindecreases the exposure toopioids(methadone).
Monitor and adjust dose.rStudy
▶Rifampicinis predicted to decrease the exposure toopioids
(oxycodone). Monitor and adjust dose.oStudy▶Rifampicinis predicted to moderately decrease the exposure
toosimertinib. Avoid.oStudy
▶Rifampicinis predicted to decrease the exposure topalbociclib.
Avoid.rStudy
▶Rifampicinis predicted to decrease the exposure to
paliperidone. Monitor and adjust dose.rStudy
▶Rifampicinis predicted to decrease the exposure to
panobinostat. Avoid.oTheoretical
▶Rifampicindecreases the exposure toparacetamol.o
Study
▶Rifampicinis predicted to decrease the exposure to
paritaprevir(with ritonavir and ombitasvir). Avoid.r
Study
▶Rifampicinis predicted to decrease the exposure topazopanib.
Avoid.rTheoretical
▶Rifampicinis predicted to decrease the exposure to
phosphodiesterase type-5 inhibitors(avanafil, tadalafil). Avoid.
rStudy
▶Rifampicinis predicted to decrease the exposure to
phosphodiesterase type-5 inhibitors(sildenafil, vardenafil).
oTheoretical
▶Rifampicinis predicted to moderately to markedly decrease
the exposure topibrentasvir. Avoid.rStudy
▶Rifampicinmoderately decreases the exposure topioglitazone.
Monitor and adjust dose.oStudy
▶Rifampicinis predicted to decrease the exposure to
pirfenidone. Avoid.oTheoretical
▶Rifampicinis predicted to moderately decrease the exposure
topitolisant.oStudy
▶Rifampicinis predicted to decrease the exposure toponatinib.
Avoid.oTheoretical
▶Rifampicinis predicted to markedly decrease the exposure to
praziquantel. Avoid.oStudy
▶Rifampicinis predicted to decrease the exposure toquetiapine.
oStudy
▶Rifampicinslightly decreases the exposure toraltegravir.
Avoid or adjust dose—consult product literature.o
Study
▶Rifampicinis predicted to decrease the exposure toranolazine.
Avoid.rStudy
▶Rifampicinis predicted to decrease the exposure toreboxetine.
oAnecdotal
▶Rifampicinis predicted to decrease the exposure to
regorafenib. Avoid.oStudy
▶Rifampicinis predicted to decrease the exposure to
repaglinide. Monitor blood glucose and adjust dose.o
Study
▶Rifampicinis predicted to markedly decrease the exposure to
ribociclib. Avoid.rStudy
▶Rifampicinmarkedly decreases the exposure torilpivirine.
Avoid.rStudy
▶Rifampicinis predicted to decrease the exposure to
risperidone. Adjust dose.oStudy
▶Rifampicinis predicted to moderately decrease the exposure
torivaroxaban. Avoid unless patient can be monitored for
signs of thrombosis.rStudy
▶Rifampicinis predicted to decrease the exposure toroflumilast.
Avoid.oStudy
▶Rifampicinis predicted to markedly decrease the exposure to
rolapitant. Avoid.rStudy
▶Rifampicinis predicted to decrease the exposure toruxolitinib.
Monitor and adjust dose.oStudy
▶Rifampicinis predicted to moderately decrease the exposure
tosaxagliptin.oStudy
▶Rifampicinmoderately decreases the exposure to the active
metabolite ofselexipag. Adjust dose.oStudy
▶Rifampicinis predicted to decrease the exposure tosimeprevir.
Avoid.rStudy
▶Rifampicinis predicted to decrease the concentration of
sirolimus. Avoid.rStudy
▶Rifampicinis predicted to decrease the exposure tosofosbuvir.
Avoid.rStudy
▶Rifampicinis predicted to decrease the exposure tosolifenacin.
oTheoretical984 Rifampicin—Rifampicin BNFC 2018 – 2019
Interactions|Appendix 1A1